News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Treasury yields fell after oil dropped on reported progress in Iran talks, reducing near-term Fed hike expectations.
  • Vertex shares plunged after Q2 results and revenue guidance that disappointed analysts, prompting downgrades and target cuts.
  • Rising rates threaten mREITs, Boeing and debt-heavy utilities due to refinancing and valuation pressure.
  • Duke Energy beat Q2 EPS expectations as demand and rate recoveries offset higher costs, enabling potential capex expansion.
  • Stablecoin activity accelerated as Western Union launched a USDC-backed Visa and Circle posted 51.5% USDC revenue growth.
  • Gartner named Zscaler and Netskope leaders in SASE/SSE, providing a positive vendor catalyst for cloud security stocks.

Latest Articles

Astera Labs Reports First Quarter 2026 Financial Results

Astera Labs Reports First Quarter 2026 Financial Results

Astera Labs announced strong first quarter fiscal 2026 financial results with record revenue of $308.4 million, reflecting 14% sequential growth and 93% year-over-year increase. The company highlighted robust demand for its PCIe 6 portfolio and newly launched Scorpio X-Series 320-lane AI fabric switch, aimed at frontier AI workloads. Astera Labs al…

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

Myriad Genetics announced Q1 2026 financial results showing a 2% revenue growth to $200.4 million driven by strong volumes in Cancer Care Continuum and Mental Health testing, offsetting declines in Prenatal Health. The company launched the Precise MRD assay and received FDA approval for MyChoice CDx test as a companion diagnostic for Zejula® in ova…

BlackLine Announces First Quarter Financial Results

BlackLine Announces First Quarter Financial Results

BlackLine, Inc. announced solid financial results for the first quarter of 2026, with 9.7% revenue growth year over year to $183.2 million, improved GAAP and non-GAAP operating margins, and increased net income. The company highlighted the commercial adoption of its AI-driven platform capabilities and raised its full-year financial guidance, expect…

Cricut, Inc. Reports First Quarter 2026 Financial Results

Cricut, Inc. Reports First Quarter 2026 Financial Results

Cricut, Inc. announced its first quarter 2026 financial results with revenue of $159.5 million, down 2% year-over-year, and net income of $20.3 million, down 15% year-over-year. The company reported growth in its platform revenue by nearly 6% and an increase in paid subscribers to just under 3.08 million. International revenue rose over 16%, making…

Korro to Participate in Upcoming Investor Conferences

Korro to Participate in Upcoming Investor Conferences

Korro Bio, a biopharmaceutical company specializing in RNA editing through its OPERA® platform, announced that key executives will participate in the HCW 4th Annual BioConnect Nasdaq Investor Conference and the 2026 RBC Capital Markets Global Healthcare Conference. These engagements aim to present their innovative genetic medicine programs and stra…

American Coastal Insurance Corporation Reports Financial Results for Its First Quarter Ended March 31, 2026

American Coastal Insurance Corporation Reports Financial Results for Its First Quarter Ended March 31, 2026

American Coastal Insurance Corporation reported net income of $19.3 million for Q1 2026, slightly down 9.8% year-over-year. Gross premiums written fell 24.5% to $149.4 million due to a softening commercial insurance market and pricing pressure. The company maintained solid underwriting discipline with a combined ratio of 66.0%. Book value per share…

Weyco Reports First Quarter 2026 Results

Weyco Reports First Quarter 2026 Results

Weyco Group, Inc. announced first quarter 2026 financial results with net sales steady at $68 million compared to Q1 2025. Operating earnings rose by 7%, and net earnings increased by 10%, driven by improved cost controls despite tariff-related cost pressures. The company is actively engaging in a tariff refund process following a Supreme Court rul…

OnKure Therapeutics Reports First Quarter 2026 Financial Results

OnKure Therapeutics Reports First Quarter 2026 Financial Results

OnKure Therapeutics reported Q1 2026 financial results highlighting a strategic focus on next-generation PI3Kα pan-mutant selective inhibitors, OKI-355 for vascular anomalies and OKI-345 for breast cancer. The company completed an oversubscribed $150 million private placement, boosting cash reserves to $192 million, expected to fund operations into…

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Verrica Pharmaceuticals announced the presentation of Phase 2 clinical data highlighting the potential abscopal effects of their novel oncolytic peptide VP-315 in treating basal cell carcinoma (BCC). The data suggest VP-315 can reduce untreated tumor lesions, indicating broader immune activation that may benefit patients with multiple BCC lesions. …

LeMaitre Q1 2026 Financial Results

LeMaitre Q1 2026 Financial Results

LeMaitre Vascular, a US-based vascular device and implant company, announced robust Q1 2026 financial results featuring an 11% increase in sales to $66.6 million, a 42% rise in EPS to $0.68, and a gross margin improvement to 72.7%. The company cited growth across all major product lines and geographical regions, supported by higher prices and manuf…

Devon Energy Reports First-Quarter 2026 Results

Devon Energy Reports First-Quarter 2026 Results

Devon Energy Corp., a leading U.S. oil and gas producer, reported its first-quarter 2026 financial and operational results and issued an outlook for the second quarter of 2026. The company highlighted its multi-basin portfolio, including a key position in the Delaware Basin, and reaffirmed its commitment to strong returns, free cash flow generation…

Supernus Announces First Quarter 2026 Financial Results

Supernus Announces First Quarter 2026 Financial Results

Supernus Pharmaceuticals (NASDAQ: SUPN) reported a 39% year-over-year increase in total revenues to $207.7 million for Q1 2026, driven by 56% growth in revenues from its four growth products including Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO. The company highlighted ongoing clinical development programs, a potential FDA submission for a second ONAPGO…

Standard BioTools Reports First Quarter 2026 Financial Results

Standard BioTools Reports First Quarter 2026 Financial Results

Standard BioTools Inc. reported first quarter 2026 financial results with revenue of $21.1 million, a 5% increase year-over-year. The company achieved a 54% reduction in operating loss and a 78% improvement in adjusted EBITDA, reinforcing its path to profitability by the end of 2026. Cash and investments totaled $524 million, supporting an aggressi…